Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Denosumab Injection Clear all
Completed Phase 3 Interventional Results available

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

NCT03292146
View directory record Official record
Conditions
Bone Density, Bone Loss, Anorexia Nervosa, Eating Disorder, Atypical Anorexia Nervosa
Interventions
Denosumab 60 MG [Prolia], Placebo Injection, Alendronate 70Mg Tab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 20, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

RANKL Inhibition and Mammographic Breast Density

NCT04067726
View directory record Official record
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

NCT02176382
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
denosumab, teriparatide, Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Denosumab on Cellular Biomarkers in the Human Breast

NCT02099461
View directory record Official record
Conditions
Healthy Volunteer, Female, Breast
Interventions
Denosumab, Percutaneous core needle breast biopsy
Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Cypress, California • Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 20, 2026, 11:45 PM EDT
Terminated Phase 2 Interventional Results available

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

NCT02758132
View directory record Official record
Conditions
Prostate Cancer
Interventions
Denosumab, Enzalutamide, Abiraterone, Prednisone
Biological · Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Osteoclast Inhibition and Bone Formation

NCT02554695
View directory record Official record
Conditions
Bone Loss, Aging
Interventions
placebo, denosumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 80 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

Denosumab and MRI Breast Imaging

NCT02613416
View directory record Official record
Conditions
Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
Alison Stopeck
Other
Eligibility
Up to 75 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

NCT04026256
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

NCT04232657
View directory record Official record
Conditions
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Interventions
Romosozumab, Denosumab, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Terminated Phase 1 Interventional Results available

Effects of Denosumab on the Pharmacokinetics of Etanercept

NCT01294397
View directory record Official record
Conditions
Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
Interventions
Etanercept, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 20, 2026, 11:45 PM EDT
Terminated Phase 4 Interventional Results available

Denosumab in Primary Hyperparathyroidism

NCT01558115
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

NCT03974100
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
GP2411, EU-Prolia (EU-authorized Prolia®)
Biological
Lead sponsor
Sandoz
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

NCT01345019
View directory record Official record
Conditions
Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
1,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
79
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 20, 2026, 11:45 PM EDT
Withdrawn No phase listed Observational

Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid

NCT03812367
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 20, 2026, 11:45 PM EDT
Withdrawn No phase listed Observational

Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis

NCT03217513
View directory record Official record
Conditions
Osteoporosis, Knee Osteoarthritis
Interventions
Not listed
Lead sponsor
Edward Fox
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 20, 2026, 11:45 PM EDT
Active, not recruiting Phase 4 Interventional

Muscle Impact of Treating Osteoporosis

NCT05666310
View directory record Official record
Conditions
Sarcopenia, Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Denosumab Placebo, Zoledronic Acid Placebo
Drug · Other
Lead sponsor
Nami Safai Haeri
Other
Eligibility
65 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Denosumab for Type 1 Diabetes

NCT06524960
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Duarte, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

NCT03620019
View directory record Official record
Conditions
Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
Interventions
Denosumab, Pembrolizumab, Nivolumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Manchester, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Terminated Phase 3 Interventional Results available

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

NCT02352753
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

NCT04729621
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

NCT02833610
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Denosumab Q4W
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Atlanta, Georgia • Boston, Massachusetts • Danvers, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 20, 2026, 11:45 PM EDT
Completed Phase 4 Interventional Results available

Preventing Osteoporosis Using Denosumab

NCT02753283
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions
denosumab, Placebo, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 11:45 PM EDT
Terminated Phase 3 Interventional Results available

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
93
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 20, 2026, 11:45 PM EDT